Summary Silence Therapeutics made considerable advancements in the development of SLN360 and SLN124 in H1 FY2020. It got FDA approval for dose escalation of SLN360. The Company entered into a partnership with AstraZeneca for the development and...
Summary The outbreak of the pandemic has led to a change in consumer preferences and priorities as the focus has shifted towards the use of technology and contact-less healthcare services The current reporting season has been challenging for ma...
Summary AstraZeneca Plc after a voluntary halt in the phase 3 trial of its coronavirus vaccine has said that the Covid-19 vaccine could still be available the end of the year The UK-based pharmaceutical company is involved in the Covid-19 vacci...
AstraZeneca plc (LON: AZN) has put on hold the phase 3 trials of its Covid-19 vaccine candidate, AZD1222, due to a suspected unfavorable reaction being developed in a UK volunteer. The vaccine maker has halted the vaccine trials voluntarily to faci...
Health care equipment & devices manufacturers/ distributors are likely to bear some additional cost and efforts due to the new UK product safety marking. The medical supplies, along with health care devices and equipment, were being tra...
Summary Dechra Pharmaceuticals revenue increased by 6.8 percent year on year in FY2020, which was supported by the full-year impact of the acquisitions. The underlying EBITDA was £142.5 million, and the EBITDA margin was 27.7 percent in F...
Summary The AstraZeneca licenced Jenner Institute of Oxford University developed vaccine candidate is in the most advanced stage of its clinical trials compared to its most other competitors being developed around the world. The vaccine’s...
Summary Several pharmaceutical companies are conducting clinical and human trials to test an effective vaccine for Covid-19. Some of the companies including AstraZeneca, GSK, Johnson & Johnson, Pfizer, and Sanofi are doing good both in term...
Summary Healthcare is perhaps the only one of the few sectors which are in the thick of business activity in these trying times in the United Kingdom. UK is home to some global pharmaceutical giants which have unparalleled technological advance...
Summary 4D Pharma announced clinical trial benefit in Phase A trial from the combined use of MRx0518 and Keytruda®. Also, disease control rate of 42 percent in 12 patients was achieved in Phase A trial. The Company is undergoing Phase...
Get a call to receive stock recommendation services from (www.kalkine.co.uk)
